EVGN - רווח לפני ריבית, מסים ופחת Evogene

Evogene Ltd. is recognized as a global expert in computational biology, developing AI solutions for the medical and agricultural sectors. EBITDA demonstrates the business's fundamental ability to generate income, while 0.00 expresses the value of the metric today. Revenue stability is supported by long-term contracts, and the active development of the R&D pipeline accelerates the release of innovative therapeutic molecules and agrochemicals.

This metric measures net cash flow from operating activities before accounting for debt obligations and depreciation, allowing for an assessment of the business's actual ability to generate cash. Monitoring the operating income before taxes and depreciation serves as a capital stress test for Evogene Ltd. (EVGN), confirming the efficiency of licensing the Scalability AI platform through the collection of royalties for genome simulation without incurring physical agricultural costs.